e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
COPD: markers and inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients?
B. Basina, T. Pertseva, L. Konopkina (Dnipropetrovsk, Ukraine)
Source:
Annual Congress 2013 –COPD: markers and inflammation
Session:
COPD: markers and inflammation
Session type:
Oral Presentation
Number:
3302
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Basina, T. Pertseva, L. Konopkina (Dnipropetrovsk, Ukraine). Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients?. Eur Respir J 2013; 42: Suppl. 57, 3302
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Effect of low dose theophylline as adjunct in treatment of COPD
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
The mechanisms of antiinflammatory effect of mucolytic therapy
Source: International Congress 2014 – Predictors
Year: 2014
Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity?
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017
Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Hyaluronic acid as a novel systemic biomarker to predict progression and severity in chronic obstructive pulmonary disease
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
The effect of conjugated linoleic acid supplementation on the nutritional status of COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
The novel myokine irisin interacts with hyaluronic acid in a cell-specific way and in association with COPD progression and severity
Source: International Congress 2016 – Emerging concepts in lung disease pathogenesis
Year: 2016
The effect of a novel anti-inflammatory agent (ODSH) on C-reactive protein in patients with an acute exacerbation of COPD
Source: Annual Congress 2009 - Acute lung injury and biomarkers
Year: 2009
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Additive effect of targeted lung denervation plus drug in patients with COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept